Dozens of drugs designed to target and clear beta-amyloid plaques in the brain have failed to prevent or halt the progression of Alzheimer’s disease….
According to an Eisai press release, the U.S. Food and Drug Administration has now granted priority review to a new anti-amyloid drug by Biogen…
On Monday, revealed that a phase 3 study of brexpiprazole — brand name Rexulti — in Alzheimer’s patients showed that the drug for major…
There were more than 140 experimental Alzheimer’s drugs in clinical trials as of the start of 2022. On the one hand, this number inspires…
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Scientists have faced obstacle after obstacle in the search for effective Alzheimer’s drugs. While there are a number of symptomatic drugs approved by the…
Vaccines are considered one of the greatest innovations in medical history. Immunizations help train the body’s immune system to recognize and respond to a…
UPDATE: 3 March 2024, 8:30 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:37 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The FDA approves a new, transdermal form of donepezil called Adlarity, a skin patch for treating Alzheimer’s symptoms. Experts say it could be easier…
In February of this year, the Centers for Medicare and Medicaid Services (CMS) released a confusing proposal to dramatically limit insurance coverage for Aduhelm,…
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The lack of effective treatments for Alzheimer’s have spurred scientists to rethink the dominant approach to tackling the disease: the amyloid hypothesis. This hypothesis…
UPDATE: 3 March 2024, 8:27 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Here’s how VOA’s 5 founders — including reporter Phil Gutis — responded to recent Aduhelm Medicare announcement. A few months ago, I received an…